+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Kidney Cancer Therapeutics & Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 68 Pages
  • January 2022
  • Region: Europe
  • Mordor Intelligence
  • ID: 5529020
UP TO OFF until Mar 31st 2024

The Europe Kidney Cancer Therapeutics & Diagnostics Market is expected to register a CAGR of 5.7% during the forecast period. The major factors driving the growth of the market in the Europe region is due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies.

According to GLOBOCAN 2018, in Germany, there were about 16,416 new kidney cancer cases in 2018 and the mortality was approximately 8,450 cases.

Furthermore, changes in lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Thus, owing to the above factors the Europe kidney cancer therapeutics & diagnostics market is expected to significant growth over the forecast period.

Key Market Trends

Clear cell RCC Segment is Expected to Hold Major Market Share in the Europe Kidney Cancer Therapeutics & Diagnostics Market

Clear cell renal cell carcinoma, or ccRCC, is a type of kidney cancer. Clear cell renal cell carcinoma is also called conventional renal cell carcinoma. Clear cell renal cell carcinoma is named after how the tumor looks under the microscope. The cells in the tumor look clear, like bubbles.

According to Kidney Cancer Care Ltd., Kidney cancer is the seventh most common cancer in the UK, which is responsible for around 12,600 new cases every year in the UK which equates to 34 cases every day and up to 30% of all people are diagnosed when in the advanced stage of the disease. Over the last decade kidney cancer incidence has risen by nearly half (47%) and is projected to rise by 26% in the UK between 2014 and 2035.

Furthermore, in 2017, EUSA Pharma and AVEO Oncology announced the first commercial launch of FOTIVDA (tivozanib) with the initiation of product sales in Germany. In the European Union, Norway and Iceland, tivozanib is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (aRCC).

Hence, with high prevalence of the disease and presence of diagnostic procedures and treatment therapies, the segment is expected to witness growth.

Competitive Landscape

The Europe Kidney Cancer Therapeutics & Diagnostics Market is moderately consolidated competitive. Product innovation and ongoing R&D activities to develop advanced technologies has helped in boosting the growth of the market. Some of the companies which are currently dominating the market are Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd, BRISTOL-MYERS SQUIBB COMPANY, Amgen Inc, Novartis AG, Pfizer Inc, and Seattle Genetics.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Number of Kidney Cancer Cases
4.2.2 Increased R&D Expenditure of Pharmaceutical Companies
4.3 Market Restraints
4.3.1 High Cost Associated with Treatment
4.3.2 Preference for Generic Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Cancer Type
5.1.1 Clear cell RCC
5.1.2 Papillary RCC
5.1.3 Chromophobe RCC
5.1.4 Urothelial carcinoma/Transitional cell carcinoma
5.1.5 Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)
5.2 By Component
5.2.1 Drugs Therapeutic Class Targeted Therapy Immunotherapy Other Therapeutic Class By Pharmacologic Class Angiogenesis Inhibitors Monoclonal Antibodies mTOR Inhibitors Cytokine Immunotherapy (IL-2)
5.2.2 Diagnostics Biopsy Imaging Tests Blood Tests Other Diagnostics
5.3 Geography
5.3.1 Europe Germany United Kingdom France Italy Spain Rest of Europe
6.1 Company Profiles
6.1.1 Pfizer Inc
6.1.2 F. Hoffmann-La Roche Ltd
6.1.3 Bayer AG
6.1.4 Novartis AG
6.1.5 Amgen Inc
6.1.6 Abbott Laboratories
6.1.7 Cerulean Pharma Inc
6.1.8 Eisai co Ltd
6.1.9 Seattle Genetic